PAREXEL’s Alberto Grignolo Named Fellow by Drug Information Association

Honored for contributing to the advancement of health care

BOSTON–(BUSINESS WIRE)–PAREXEL International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that Alberto
Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting, has been
named a Fellow by the Drug Information Association (DIA). Dr. Grignolo
received the organization’s highest distinction during the 53rd
DIA Annual Meeting in Chicago. The honorary designation recognizes Dr.
Grignolo’s contributions to the advancement of health care and his
leadership within DIA.


Dr. Grignolo, a 25-year veteran of PAREXEL, is a global expert on and a
frequent contributor to various regulatory, drug development and
management topics. At PAREXEL, he developed the Company’s Worldwide
Regulatory Affairs and Drug Development Consulting Practices. He also
established PAREXEL’s Consulting Services in Japan during an extended
assignment there. Dr. Grignolo is executive sponsor of a number of
global development programs and advises clients in the areas of drug
development strategy, regulatory negotiation, and best regulatory and
clinical practices.

Additionally, Dr. Grignolo served on the DIA Board of Directors, has
been on the faculty of DIA’s Regulatory Affairs training courses for
more than a decade, and is the Editor of DIA’s member magazine, Global
Forum
. In 2015, Dr. Grignolo was awarded the DIA Inspire Award
(Global Connector) for his meritorious service through leadership roles
that have advanced DIA’s mission to foster innovation and to improve
health and well-being worldwide.

“Alberto’s quarter century of leadership at PAREXEL has furthered our
mission of helping clients deliver new therapies to patients sooner,”
said Josef von Rickenbach, Chairman and CEO, PAREXEL. “This recognition
as a DIA Fellow also showcases his dedication to the advancement of
health care. We are proud of his continued service and commitment to our
Company and the many clients he serves.”

“Alberto personifies DIA. His commitment and passion for health care
product innovation, along with his willingness to share candid insights
from his treasure trove of knowledge, characterize his many
contributions to DIA over the decades. We are thrilled to count Alberto
amongst our leaders and volunteers, and honored to bestow upon him this
well-deserved recognition of Fellow of DIA,” said Barbara Lopez Kunz,
Global Chief Executive, DIA.

About Fellow of DIA Program

Membership into the Fellows of DIA Program is a unique distinction
awarded to long-term, highly engaged members who continue to contribute
to DIA in exemplary ways. This is an honorary recognition bestowed on
less than 1 percent of DIA’s membership.

Fellows of DIA have demonstrated active support of the advancement of
health care and the health care products arena through leadership roles
for a minimum of 15 years and have proven engagement in DIA through key
volunteer roles in support of major DIA projects or initiatives.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical
services company, providing a broad range of expertise-based clinical
research, consulting, medical communications, and technology solutions
and services to the worldwide pharmaceutical, biotechnology, and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to clinical
pharmacology, clinical trials management, and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including medical
imaging, to facilitate the integrated clinical development and
regulatory information management process. Headquartered near Boston,
Massachusetts, PAREXEL has offices in 86 locations in 51 countries
around the world, and had approximately 19,370 employees in the third
quarter. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks
of PAREXEL International Corporation or its affiliates. All other
trademarks are the property of their respective owners.

This release contains “forward-looking” statements regarding future
results and events. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed forward-looking
statements. Without limiting the foregoing, the words “believes,”
“anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,”
“projects,” “will,” “would,” “could,” “should,” “targets,” and similar
expressions are also intended to identify forward-looking statements.
The forward-looking statements in this release involve a number of risks
and uncertainties. Such factors and others are discussed in the section
entitled “Risk Factors” of the Company’s most recent Annual Report on
Form 10-K and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these forward-looking
statements in the future. These forward-looking statements should not be
relied upon as representing the Company’s estimates or views as of any
date subsequent to the date of this press release.

Contacts

Media:
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie@PAREXEL.com
or
Kathryn
McMahon, PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
or
Investors:
Ronald
Aldridge
Tel.: +1-781-434-4753
Email: ron.aldridge@PAREXEL.com